Literature DB >> 1761121

Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation.

L Marsa-Vila1, N C Gorin, J P Laporte, M Labopin, M C Dupuy-Montbrun, L Fouillard, F Isnard, A Najman.   

Abstract

Veno-occlusive disease (VOD) is a major cause of toxic death after autologous bone marrow transplantation (ABMT). We studied the potential role of continuous administration of low-dose heparin for VOD prevention in 234 consecutive patients who underwent ABMT in our institution. The population consisted of 98 patients autografted before October 1984 who did not receive heparin, and a series of 136 patients autografted from October 1984 to March 1989 containing 98 patients included in a randomized trial comparing heparin administration (n = 52) vs no heparin (n = 46), and an additional group of 38 patients who received non-randomized heparin in view of high-risk criteria to develop VOD (n = 31) or other reasons unrelated to VOD (n = 7). Overall, 90 patients (38%) received heparin and 144 (62%) did not. The global incidence of VOD was 13/234 (5-5%). Heparin did not reduce the risk of VOD in all subgroups studied. In particular, in the randomized trial, the incidence of VOD was 2.2% in the group without heparin vs 7-7% in the group receiving heparin. We analyzed in depth the 13 patients who developed VOD and we compared them to a control group of 13 patients pair-matched for age, sex, diagnosis and preparative regimen, who did not develop VOD. We found that abnormal LFT before ABMT predisposed patients to VOD; refractoriness to platelet transfusion was observed in 85% of the patients in the VOD group vs 15% in the control group (p less than 0.05). VOD patients had an increased requirement for red cells and platelet transfusions, a lower recovery (R less than 25%) after the second and third platelet transfusion, and shorter intervals separating the first four platelet transfusions. Further, the platelet reconstitution after ABMT in the VOD group was slower in comparison to the control group (p less than 0.01). Again, in this pair-matched analysis continuous infusion of low-dose heparin did not prevent VOD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761121     DOI: 10.1111/j.1600-0609.1991.tb01859.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

Review 1.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24

2.  Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.

Authors:  G Battipaglia; M Labopin; A Candoni; R Fanin; J El Cheikh; D Blaise; M Michallet; A Ruggeri; N Contentin; J M Ribera; M Stadler; J Sierra; P A von dem Borne; A Bloor; G Socié; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

Review 3.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

4.  Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.

Authors:  Jae-Ho Yoon; Gi June Min; Sung-Soo Park; Silvia Park; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong Wook Lee; Hee-Je Kim; Seok Lee
Journal:  Bone Marrow Transplant       Date:  2021-02-01       Impact factor: 5.483

5.  Antithrombin III Utilization in a Large Teaching Hospital.

Authors:  Cristina M Salas; Marta A Miyares
Journal:  P T       Date:  2013-12

6.  Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide.

Authors:  M J Jenner; I N Micallef; A Z Rohatiner; S M Kelsey; A C Newland; J D Cavenagh
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

Review 7.  Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies.

Authors:  Maria Giuseppina Cefalo; Palma Maurizi; Annalisa Arlotta; Maria Scalzone; Giorgio Attinà; Antonio Ruggiero; Riccardo Riccardi
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

Review 8.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

Review 9.  Hepatic venous outflow obstruction: three similar syndromes.

Authors:  Ulas-Darda Bayraktar; Soley Seren; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

Review 10.  Intensive care and oncology.

Authors:  J P Sculier
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.